GlaxoSmithKline is banking on a major clinical trial to revive its flagging respiratory medicine business, with billions of dollars of sales riding on a positive result.
Data from the so-called SUMMIT study, designed to show GSK's Breo can prolong lives of patients with chronic lung disease, are expected as early as next month, nine years after a similar study with GSK's older drug Advair failed by a whisker.
This time GSK reckons it has a better chance, since the new trial, with 16,500 patients, has more statistical power than the 6,100-patient Advair trial, known as TORCH. GSK has also chosen higher-risk patients with heart issues for the new study.
Help employers find you! Check out all the jobs and post your resume.
Data from the so-called SUMMIT study, designed to show GSK's Breo can prolong lives of patients with chronic lung disease, are expected as early as next month, nine years after a similar study with GSK's older drug Advair failed by a whisker.
This time GSK reckons it has a better chance, since the new trial, with 16,500 patients, has more statistical power than the 6,100-patient Advair trial, known as TORCH. GSK has also chosen higher-risk patients with heart issues for the new study.
Help employers find you! Check out all the jobs and post your resume.
